{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T18:23:56Z","timestamp":1790965436668,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s13555-025-01456-5","type":"journal-article","created":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T23:30:18Z","timestamp":1749598218000},"page":"2117-2130","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Patient-Reported Outcomes by Baseline Body Surface Area Involvement Among Individuals Initiating Biologic Therapy: Results from the CorEvitas Psoriasis Registry"],"prefix":"10.1007","volume":"15","author":[{"given":"April W.","family":"Armstrong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven R.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Fitzgerald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore","family":"Alkousakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Sima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung-Joo","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra I.","family":"Main","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saakshi","family":"Khattri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Stein Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,11]]},"reference":[{"issue":"8","key":"1456_CR1","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1001\/jamadermatol.2021.2007","volume":"157","author":"AW Armstrong","year":"2021","unstructured":"Armstrong AW, Mehta MD, Schupp CW, Gondo GC, Bell SJ, Griffiths CEM. Psoriasis prevalence in adults in the United States. JAMA Dermatol. 2021;157(8):940\u20136. https:\/\/doi.org\/10.1001\/jamadermatol.2021.2007.","journal-title":"JAMA Dermatol"},{"issue":"2 Pt 1","key":"1456_CR2","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1067\/mjd.2000.106374","volume":"43","author":"GG Krueger","year":"2000","unstructured":"Krueger GG, Feldman SR, Camisa C, et al. Two considerations for patients with psoriasis and their clinicians: What defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol. 2000;43(2 Pt 1):281\u20135. https:\/\/doi.org\/10.1067\/mjd.2000.106374.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1456_CR3","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","volume":"80","author":"A Menter","year":"2019","unstructured":"Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029\u201372. https:\/\/doi.org\/10.1016\/j.jaad.2018.11.057.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1456_CR4","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jaad.2019.08.026","volume":"82","author":"B Strober","year":"2020","unstructured":"Strober B, Ryan C, van de Kerkhof P, et al. Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. J Am Acad Dermatol. 2020;82(1):117\u201322. https:\/\/doi.org\/10.1016\/j.jaad.2019.08.026.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1456_CR5","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/jdv.16966","volume":"35","author":"NM Golbari","year":"2021","unstructured":"Golbari NM, van der Walt JM, Blauvelt A, Ryan C, van de Kerkhof P, Kimball AB. Psoriasis severity: commonly used clinical thresholds may not adequately convey patient impact. J Eur Acad Dermatol Venereol. 2021;35(2):417\u201321. https:\/\/doi.org\/10.1111\/jdv.16966.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"1456_CR6","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1016\/j.jid.2022.02.013","volume":"142","author":"J Takeshita","year":"2022","unstructured":"Takeshita J, Augustin M, de Jong EMGJ, et al. Health-related QOL differs by race\/ethnicity in North American patients with psoriasis: results from PSOLAR. J Invest Dermatol. 2022;142(9):2528-31.e3. https:\/\/doi.org\/10.1016\/j.jid.2022.02.013.","journal-title":"J Invest Dermatol"},{"issue":"3","key":"1456_CR7","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s40257-017-0332-7","volume":"19","author":"BP Kaufman","year":"2018","unstructured":"Kaufman BP, Alexis AF. Psoriasis in skin of color: insights into the epidemiology, clinical presentation, genetics, quality-of-life impact, and treatment of psoriasis in non-white racial\/ethnic groups. Am J Clin Dermatol. 2018;19(3):405\u201323. https:\/\/doi.org\/10.1007\/s40257-017-0332-7.","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"1456_CR8","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1111\/bjd.17128","volume":"179","author":"M Augustin","year":"2018","unstructured":"Augustin M, Langenbruch A, Gutknecht M, et al. Definition of psoriasis severity in routine clinical care: current guidelines fail to capture the complexity of long-term psoriasis management. Br J Dermatol. 2018;179(6):1385\u201391. https:\/\/doi.org\/10.1111\/bjd.17128.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1456_CR9","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12589","volume":"31","author":"JF Merola","year":"2018","unstructured":"Merola JF, Qureshi A, Husni ME. Underdiagnosed and undertreated psoriasis: nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails. Dermatol Ther. 2018;31(3):e12589. https:\/\/doi.org\/10.1111\/dth.12589.","journal-title":"Dermatol Ther"},{"issue":"6","key":"1456_CR10","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1007\/s13555-023-00929-9","volume":"13","author":"JF Merola","year":"2023","unstructured":"Merola JF, Ogdie A, Gottlieb AB, et al. Patient and physician perceptions of psoriatic disease in the United States: results from the UPLIFT survey. Dermatol Ther (Heidelb). 2023;13(6):1329\u201346. https:\/\/doi.org\/10.1007\/s13555-023-00929-9.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"12","key":"1456_CR11","doi-asserted-by":"publisher","first-page":"e995","DOI":"10.1111\/jdv.18400","volume":"36","author":"N da Silva","year":"2022","unstructured":"da Silva N, Augustin M, Hilbring C, von St\u00fclpnagel CC, Sommer R. Patient-physician (dis)agreement on their reports of body surface area affected by psoriasis and its associations with disease burden. J Eur Acad Dermatol Venereol. 2022;36(12):e995\u20137. https:\/\/doi.org\/10.1111\/jdv.18400.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1456_CR12","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jaad.2017.10.012","volume":"78","author":"B Strober","year":"2018","unstructured":"Strober B, Karki C, Mason M, et al. Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: results from the Corrona Psoriasis Registry. J Am Acad Dermatol. 2018;78(2):323\u201332. https:\/\/doi.org\/10.1016\/j.jaad.2017.10.012.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"1456_CR13","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1001\/archderm.1992.01680180125022","volume":"128","author":"CC Long","year":"1992","unstructured":"Long CC, Finlay AY, Averill RW. The rule of hand: 4\u00a0hand areas = 2 FTU = 1 g. Arch Dermatol. 1992;128(8):1129\u201330.","journal-title":"Arch Dermatol"},{"issue":"3","key":"1456_CR14","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/0305-4179(95)00118-2","volume":"22","author":"ND Rossiter","year":"1996","unstructured":"Rossiter ND, Chapman P, Haywood IA. How big is a hand? Burns. 1996;22(3):230\u20131. https:\/\/doi.org\/10.1016\/0305-4179(95)00118-2.","journal-title":"Burns"},{"issue":"5","key":"1456_CR15","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1111\/j.1365-2133.2007.08183.x","volume":"157","author":"CL Thomas","year":"2007","unstructured":"Thomas CL, Finlay AY. The \u2018handprint\u2019 approximates to 1% of the total body surface area whereas the \u201cpalm minus the fingers\u201d does not. Br J Dermatol. 2007;157(5):1080\u20131. https:\/\/doi.org\/10.1111\/j.1365-2133.2007.08183.x.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1456_CR16","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210\u20136. https:\/\/doi.org\/10.1111\/j.1365-2230.1994.tb01167.x.","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"1456_CR17","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/j.0022-202X.2005.23621.x","volume":"125","author":"Y Hongbo","year":"2005","unstructured":"Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY. Translating the science of quality of life into practice: What do Dermatology Life Quality Index scores mean? J Invest Dermatol. 2005;125(4):659\u201364. https:\/\/doi.org\/10.1111\/j.0022-202X.2005.23621.x.","journal-title":"J Invest Dermatol"},{"issue":"6","key":"1456_CR18","doi-asserted-by":"publisher","first-page":"759","DOI":"10.2340\/00015555-2642","volume":"97","author":"A Reich","year":"2017","unstructured":"Reich A, Chatzigeorkidis E, Zeidler C, et al. Tailoring the cut-off values of the visual analogue scale and numeric rating scale in itch assessment. Acta Derm Venereol. 2017;97(6):759\u201360. https:\/\/doi.org\/10.2340\/00015555-2642.","journal-title":"Acta Derm Venereol"},{"issue":"7","key":"1456_CR19","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/s1526-5900(03)00716-8","volume":"4","author":"MP Jensen","year":"2003","unstructured":"Jensen MP, Chen C, Brugger AM. Interpretation of visual analog scale ratings and change scores: a reanalysis of two clinical trials of postoperative pain. J Pain. 2003;4(7):407\u201314. https:\/\/doi.org\/10.1016\/s1526-5900(03)00716-8.","journal-title":"J Pain"},{"key":"1456_CR20","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1136\/annrheumdis-2021-eular.3346","volume":"80","author":"A Fazaa","year":"2021","unstructured":"Fazaa A, Boussaa H, Ouenniche K, et al. Optimal assessment of fatigue in rheumatoid arthritis: visual analog scale versus Functional Assessment of Chronic Illness Therapy\u2014Fatigue. Ann Rheum Dis. 2021;80:1113\u20134. https:\/\/doi.org\/10.1136\/annrheumdis-2021-eular.3346.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1456_CR21","first-page":"469","volume":"27","author":"GH Ibrahim","year":"2009","unstructured":"Ibrahim GH, Buch MH, Lawson C, Waxman R, Helliwell PS. Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: the Psoriasis Epidemiology Screening Tool (PEST) questionnaire. Clin Exp Rheumatol. 2009;27(3):469\u201374.","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"1456_CR22","first-page":"13","volume":"1","author":"ZW Birnbaum","year":"1956","unstructured":"Birnbaum ZW. On a use of the Mann-Whitney statistic. Proceedings of the Third Berkeley Symposium on Mathematical Statistics and Probability. Univ California Press. 1956;1(3):13\u20138.","journal-title":"Univ California Press"},{"issue":"10","key":"1456_CR23","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.ad.2014.02.015","volume":"105","author":"M S\u00e1nchez-Rega\u00f1a","year":"2014","unstructured":"S\u00e1nchez-Rega\u00f1a M, Aldunce Soto MJ, Belinch\u00f3n Romero I, et al. Evidence-based guidelines of the Spanish psoriasis group on the use of biologic therapy in patients with psoriasis in difficult-to-treat sites (nails, scalp, palms, and soles). Actas Dermosifiliogr. 2014;105(10):923\u201334. https:\/\/doi.org\/10.1016\/j.ad.2014.02.015.","journal-title":"Actas Dermosifiliogr"},{"issue":"11","key":"1456_CR24","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1007\/s13555-023-01012-z","volume":"13","author":"A-M Orbai","year":"2023","unstructured":"Orbai A-M, Chakravarty SD, You Y, Shawi M, Yang Y-W, Merola JF. Efficacy of guselkumab in treating nails, scalp, hands, and feet in patients with psoriasis and self-reported psoriatic arthritis. Dermatol Ther (Heidelb). 2023;13(11):2859\u201368. https:\/\/doi.org\/10.1007\/s13555-023-01012-z.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"9","key":"1456_CR25","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/1346-8138.16865","volume":"50","author":"SJ Jo","year":"2023","unstructured":"Jo SJ, Huang Y-H, Tsai T-F, et al. Efficacy of guselkumab in difficult-to-treat psoriasis regions: data from VOYAGE 1 and VOYAGE 2 Asian subpopulations. J Dermatol. 2023;50(9):1180\u20139. https:\/\/doi.org\/10.1111\/1346-8138.16865.","journal-title":"J Dermatol"},{"issue":"12","key":"1456_CR26","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1007\/s13555-024-01295-w","volume":"14","author":"JF Merola","year":"2024","unstructured":"Merola JF, Gottlieb AB, Pinter A, et al. Bimekizumab efficacy in high-impact areas: pooled 2-year analysis in scalp, nail, and palmoplantar psoriasis from phase\u00a03\/3b randomized controlled trials. Dermatol Ther (Heidelb). 2024;14(12):3291\u2013306. https:\/\/doi.org\/10.1007\/s13555-024-01295-w.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"5","key":"1456_CR27","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1111\/jdv.19748","volume":"38","author":"B Strober","year":"2024","unstructured":"Strober B, Bachelez H, Crowley J, et al. Efficacy of long-term risankizumab treatment for moderate-to-severe plaque psoriasis: subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256\u00a0weeks (LIMMitless trial). J Eur Acad Dermatol Venereol. 2024;38(5):864\u201372. https:\/\/doi.org\/10.1111\/jdv.19748.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1456_CR28","doi-asserted-by":"publisher","first-page":"247553032413020","DOI":"10.1177\/24755303241302070","volume":"21","author":"B Strober","year":"2024","unstructured":"Strober B, Zhong Y, Sima A, et al. Criteria for identifying candidates for systemic psoriasis treatment in the real world: application of the International Psoriasis Council Guidelines in patients in North America. J Psoriasis Psoriatic Arthritis. 2024;21:24755303241302070. https:\/\/doi.org\/10.1177\/24755303241302070.","journal-title":"J Psoriasis Psoriatic Arthritis"},{"issue":"Suppl 2","key":"1456_CR29","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3899\/jrheum.2024-0655","volume":"51","author":"GD Ball","year":"2024","unstructured":"Ball GD, Hamade H, Gottlieb AB, Kirby B, Callis Duffin K. GRAPPA point-counterpoint: should biologics be used for mild psoriasis? J Rheumatol. 2024;51(Suppl 2):39\u201342. https:\/\/doi.org\/10.3899\/jrheum.2024-0655.","journal-title":"J Rheumatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01456-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01456-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01456-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T19:11:29Z","timestamp":1757185889000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01456-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,11]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1456"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01456-5","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,11]]},"assertion":[{"value":"28 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"April W. Armstrong has served as a research investigator and\/or consultant to AbbVie, Bristol Myers Squibb, Dermavant, Dermira, Eli Lilly, Johnson & Johnson, KHK, Leo, Modernizing Medicine, Novartis, Ortho Dermatologics, Regeneron, Sanofi, Sun Pharma, and UCB. Steven R. Feldman has received research, speaking and\/or consulting support from: AbbVie, Accordant, Almirall, Amgen, Arcutis, Arena, Argenx, Biocon, Boehringer Ingelheim, Bristol Myers Squibb, Caremark, Celgene, Dermavant, Eli Lilly, Eurofins, Forte, Galderma, GlaxoSmithKline\/Stiefel, Helsinn, Informa, Johnson & Johnson, Leo Pharma, Menlo, Merck, Mylan, Novan, Novartis, Ortho Dermatology, Pfizer, Qurient, Regeneron, Samsung, Sanofi, Sun Pharma, Teladoc, the National Biological Corporation, the National Psoriasis Foundation, UCB, UpToDate, and vTv Therapeutics. He is founder and part owner of Causa Research and holds stock in Sensal Health. Steven R. Feldman is an Editorial Board member of Dermatology and Therapy. Steven R. Feldman was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Timothy Fitzgerald and Theodore Alkousakis are employees and shareholders of Johnson & Johnson. Adam Sima is an employee of CorEvitas, LLC, and a shareholder of Thermo Fisher Scientific. Hyung-Joo Kang is an employee of CorEvitas, LLC. Alvin Li is an employee of CorEvitas, LLC, and a stockholder of Eli Lilly. Sandra I. Main is a former employee of CorEvitas, LLC. She is currently an employee of the Health Plan of San Joaquin. Saakshi Khattri has received support for research from Bristol Myers Squibb, Celgene, LEO, Pfizer, and Takeda; as a speaker from AbbVie, Arcutis, Bristol Myers Squibb, Eli Lilly, Johnson & Johnson, LEO, Pfizer, Regeneron, Sanofi, and\u00a0UCB; and as a consultant for AbbVie, Eli Lilly, Johnson & Johnson, Regeneron, Sanofi, and UCB. Linda Stein Gold is an investigator\/advisor and\/or speaker for AbbVie, Amgen, Arcutis, Bristol Myers Squibb, Dermavant, Eli Lilly, Johnson & Johnson, Novartis, Pfizer, and UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was performed in accordance with the Declaration of Helsinki and Guidelines for Good Pharmacoepidemiology Practice (GPP). All participating investigators were required to obtain full board approval for conducting noninterventional research involving human subjects with a limited dataset. Sponsor approval and continuing review was obtained through a central institutional review board (IRB; Advarra, Protocol number is Pro00051221). For academic investigative sites that did not receive a waiver to use the central IRB, full board approval was obtained from the respective governing IRBs, and documentation of approval was submitted to CorEvitas, LLC, prior to the initiation of any study procedures. All patients in the registry were required to provide written informed consent and authorization prior to participating.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}